Table of Content
About Keystone Nano
Nano-delivery of therapeutics has been proven to be a successful concept, and is gaining commercial traction following the approval of Abraxane and Doxil. Nano-delivery is forecast to be a substantial element of future therapeutics, perhaps comprising as much as 40% of the therapies sold, representing a marketplace of tens of billions of dollars.
Phototherapy has been developed and tested extensively, but does not currently play a very significant role in cancer therapy. This is in part because of inherent challenges associated with the delivery of photosensitizers, the stability of these agents, and the ability to deliver an appropriate excitation agent.
Keystone Nano’s PINT program is quite unique. An imaging agent – indocyanine green – is coated in a NanoJacket - a calcium phosphosilicate nanoparticle (Figure 1.). This particle can be functionalized with polyethylene glycols (PEG), or a variety of other moieties, to target delivery of the active to the tumor.
Figure 1. Keystone's "NanoJacket" particle, shown with indocyanide green payload and surface functionalization.
In experiments done to date, a PEGylated NanoJacketed ICG, administered intravenously, has been shown to accumulate in cancerous tumors in animals. By administering light in the near-infrared, which penetrates tissue quite effectively, the ICG in the tumors can then be excited, creating a local immune response which shrinks or eliminates the tumor.
Naked ICG is an approved imaging agent at approximately 2,000 times the dose required for PINT. The mechanism of action of the NanoJacketed ICG has been studied, understood, and published.
Keystone is interested in completing the development and optimization of the NanoJacketed ICG program, as it is a novel and potentially low-toxicity way of treating cancerous tumors. The therapy can likely be used in concert with current chemotherapeutics and will contribute to the overall treatment efficacy.
The process of development is relatively straightforward, featuring safety studies to enablea Investigational New Drug (IND) application, the filing of the IND itself, and testing in humans.
About Keystone Nano
Keystone Nano was formed in 2006 based on nano-expertise at Penn State University and Penn State Hershey Medical. The company has created a range of nano- particles designed to improve therapeutics for both internal programs and for clients.
Keystone has been awarded contracts by ten leading pharmaceutical and biotechnology companies and grants by the National Cancer Institute and other granting organizations including contracts and grants associated with novel ways to create siRNA loaded and guided nanoparticles.
Keystone Nano’s PhotoImmunoNanoTherapy Program builds upon the investigations of Dr. James Adair and his team at Penn State University and Dr. Mark Kester and his team at Penn State Hershey. Together they have studied the therapeutic and mechanisms of PINT. Dr. Adair serves as Keystone’s Chief Science Officer and Dr. Kester serves as Keystone’s Chief Medical Officer.
This information has been sourced, reviewed and adapted from materials provided by Keystone Nano.
For more information on this source, please visit Keystone Nano.